SCHEMBL1922598

SCHEMBL1922598

CC(C)(C)OC(=O)N1CCC(CCCOc2ccc(CC(=O)O)c(F)c2)CC1

nearest known ligand 0.71

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 16/20 0.71
▸ KCNH2 Q12809 1/20 0.47
▸ DPP4 P27487 1/20 0.46
▸ SCN9A Q15858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23214796 0.90 GPR119 (0.69) GPR119KCNH2SCN9A
SCHEMBL29843762 0.90 GPR119 (0.69) GPR119KCNH2SCN9A
SCHEMBL24437577 0.89 GPR119 (0.67) GPR119KCNH2DPP4SCN9A
SCHEMBL27086551 0.87 GPR119 (0.56) GPR119KCNH2
SCHEMBL29843792 0.87 GPR119 (0.65) GPR119KCNH2SCN9A
SCHEMBL23215744 0.87 GPR119 (0.65) GPR119KCNH2SCN9A
SCHEMBL3226905 0.87 GPR119 (0.78) GPR119SCN9A
SCHEMBL1575291 0.86 GPR119 (0.74) GPR119SCN9A
SCHEMBL2387212 0.86 GPR119 (0.63) GPR119KCNH2SCN9A
SCHEMBL1576133 0.85 GPR119 (0.75) GPR119SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114945560-B GPR119 agonists 卡尔优普公司 2024-08-13 — — CN disclosed
US-20230061736-A1 GPR119 AGONISTS KALLYOPE, INC. 2023-03-02 — — US disclosed
US-20230061736-A1 GPR119 AGONISTS KALLYOPE, INC. 2023-03-02 — — US disclosed
US-11512065-B2 GPR119 agonists KALLYOPE, INC. (US) 2022-11-29 — — US disclosed
CN-114945560-A GPR119 agonists 卡尔优普公司 2022-08-26 — — CN disclosed
EP-4041722-A1 GPR119 AGONISTS Kallyope, Inc. (US) 2022-08-17 — — EP disclosed
US-20220153719-A1 GPR119 AGONISTS KALLYOPE, INC. 2022-05-19 — — US disclosed
US-20220153719-A1 GPR119 AGONISTS KALLYOPE, INC. 2022-05-19 — — US disclosed
WO-2021071837-A1 GPR119 AGONISTS KALLYOPE, INC. (US) 2021-04-15 — — WO disclosed
WO-2021071837-A1 GPR119 AGONISTS KALLYOPE, INC. (US) 2021-04-15 — — WO disclosed
US-20110212939-A1 Heterocyclic GPCR Agonists PROSIDION LIMITED (GB) 2011-09-01 — — US disclosed
US-20110212939-A1 Heterocyclic GPCR Agonists PROSIDION LIMITED (GB) 2011-09-01 — — US disclosed
US-20110212939-A1 Heterocyclic GPCR Agonists PROSIDION LIMITED (GB) 2011-09-01 — — US disclosed
EP-2328867-A1 HETEROCYCLIC GPCR AGONISTS Prosidion Limited (GB) 2011-06-08 — — EP disclosed
WO-2010004347-A1 HETEROCYCLIC GPCR AGONISTS PROSIDION LIMITED (GB) 2010-01-14 — — WO disclosed
WO-2010004347-A1 HETEROCYCLIC GPCR AGONISTS PROSIDION LIMITED (GB) 2010-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11512065-B2 GPR119 agonists GPR119, GLP1R, GCGR GPR119 1/4885KCNH2 4507/4885DPP4 682/4885
US-20110212939-A1 Heterocyclic GPCR Agonists GPR119, GCGR, GPR27 GPR119 1/4885KCNH2 1299/4885DPP4 613/4885
US-20230061736-A1 GPR119 AGONISTS GPR119, GLP1R, GCGR GPR119 1/4885KCNH2 4507/4885DPP4 682/4885
US-20220153719-A1 GPR119 AGONISTS GPR119, GLP1R, GCGR GPR119 1/4885KCNH2 4507/4885DPP4 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback